Clinical Trial

Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 18, 2024 (before its estimated August 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
To assess the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (with symptomatic dysphagia or oligometastatic disease)，and to evaluate the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (without symptomatic dysphagia or oligometastatic disease).
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06464614
Lead Sponsor The First Affiliated Hospital of Henan University of Science and Technology
Conditions Esophageal Cancer
Enrollment 54 participants
Start Date 2024-07-15
Primary Completion 2025-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2024-06-18